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Abstract
Background: The rate of forced expiratory volume in 1 second (FEV1) decline ("beta”) is a marker of chronic
obstructive pulmonary disease risk. The reduction in beta after quitting smoking is an upper limit for the reduction
achievable from switching to novel nicotine delivery products. We review available evidence to estimate this
reduction and quantify the relationship of smoking to beta.
Methods: Studies were identified, in healthy individuals or patients with respiratory disease, that provided data on
beta over at least 2 years of follow-up, separately for those who gave up smoking and other smoking groups.
Publications to June 2010 were considered. Independent beta estimates were derived for four main smoking
groups: never smokers, ex-smokers (before baseline), quitters (during follow-up) and continuing smokers.
Unweighted and inverse variance-weighted regression analyses compared betas in the smoking groups, and in
continuing smokers by amount smoked, and estimated whether beta or beta differences between smoking groups
varied by age, sex and other factors.
Results: Forty-seven studies had relevant data, 28 for both sexes and 19 for males. Sixteen studies started before
1970. Mean follow-up was 11 years. On the basis of weighted analysis of 303 betas for the four smoking groups,
never smokers had a beta 10.8 mL/yr (95% confidence interval (CI), 8.9 to 12.8) less than continuing smokers. Betas
for ex-smokers were 12.4 mL/yr (95% CI, 10.1 to 14.7) less than for continuing smokers, and for quitters, 8.5 mL/yr
(95% CI, 5.6 to 11.4) less. These betas were similar to that for never smokers. In continuing smokers, beta increased
0.33 mL/yr per cigarette/day. Beta differences between continuing smokers and those who gave up were greater
in patients with respiratory disease or with reduced baseline lung function, but were not clearly related to age or
sex.
Conclusion: The available data have numerous limitations, but clearly show that continuing smokers have a beta
that is dose-related and over 10 mL/yr greater than in never smokers, ex-smokers or quitters. The greater decline in
those with respiratory disease or reduced lung function is consistent with some smokers having a more rapid rate
of FEV1 decline. These results help in designing studies comparing continuing smokers of conventional cigarettes
and switchers to novel products.
Background
It is generally believed that 15% to 20% of all long-term
regular smokers will develop clinically overt chronic
obstructive pulmonary disease (COPD) and that most
COPD cases worldwide are attributable to cigarette
smoking [1]. COPD, along with ischaemic heart disease
and lung cancer, is a major contributor to the number
of deaths caused by smoking [2]. In this paper, we
attempt to provide information relevant to determining
the maximum reduction in risk of COPD that might be
achieved from the introduction of new-generation nico-
tine delivery products that are currently being developed
with the aim of substantially reducing the risks of
tobacco-related disease. There are two underlying
assumptions: that any benefits from the introduction of
these products cannot exceed those of giving up smok-
ing and that the rate of decline over time in forced
expiratory volume in 1 second (FEV1) is a reliable mar-
ker of the risk of COPD. FEV1 is also a marker of other
respiratory diseases such as asthma, pulmonary fibrosis
or cystic fibrosis. The information we provide should
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the use of non-nicotine-containing drugs in the area of
smoking cessation and more generally in accurately con-
veying the hazards of smoking.
We present a systematic review of the epidemiological
evidence on the relationship of smoking status to the
rate of FEV1 decline. While our major interest is in the
comparison of rates in continuing smokers and those
who gave up, we also summarize information on the
rate of FEV1 decline in never smokers and on the rela-
tionship of FEV1 decline to amount smoked. We also
investigate how differences in the rate of FEV1 decline
by smoking status are affected by other factors, with the
aim of identifying those subgroups that show the largest
differences between continuing smokers and those who
give up smoking.
It is well known that continuing smokers have an
average rate of decline in FEV1 that is substantially
greater than that of people who have never smoked [2],
and a recent review by Willemse et al. [3] summarizes
some data demonstrating that giving up smoking
reduces the rate of decline in smokers without chronic
symptoms, in smokers with nonobstructive chronic
bronchitis and in smokers with COPD. However, sum-
mary estimates, based on all available data, of the extent
o ft h ed e c l i n ei nt h o s ew h og i v eu ps m o k i n gr e l a t i v et o
those who continue to smoke is not available in the lit-
erature, and a major aim of our paper is to provide this
information.
We restrict attention to studies providing data on FEV1
in the same individuals at more than one time point and
also data for those who give up smoking. Four smoking
groups are particularly relevant to the analyses, and, to
avoid confusion, we henceforward consistently describe
them as “never smokers”, “ex-smokers”, “quitters” and
“continuing smokers”.W ed e f i n e“quitters” as subjects
smoking at the start of the follow-up period but not still
smoking at the end, and “ex-smokers” as those who had
given up smoking by the start of the follow-up period
and did not resume smoking during it. “Continuing smo-
kers” are those reporting current smoking at the start
and end of the period, and “never smokers” are those
reporting never having smoked at both time points. For
convenience, we also routinely use the term “beta” to
mean the estimated rate of decline of FEV1 in millilitres
per year over the follow-up period, with a positive beta
implying a lower FEV1 at the end of the period. Beta is
often used in statistical contexts to describe the slope of
a line.
Methods
Selection of studies
Studies selected had to satisfy five conditions: (1) FEV1
must be measured in the same individuals at least twice
over a period of at least 2 years; (2) data must be
reported separately for those who give up smoking, with
randomized studies reporting results only by advice to
quit smoking being excluded;( 3 )r e s u l t sf o raq u a n t i t a -
tive index of FEV1 decline over a period must be avail-
able directly or calculable from the data presented; (4)
subjects studied must be adults (or present results for
an age group, such as 15+ years, consisting predomi-
nantly of adults); and (5) subjects studied may be
healthy individuals or patients with COPD, chronic
bronchitis or emphysema, but not patients with other
specific conditions (for example, a1-antitrypsin defi-
ciency) or workers in occupations with a high risk of
disease (for example, miners).
Relevant publications were initially sought from a
MedLine search conducted on 6 April 2009, on “(Lung
function or FEV1 or decline in FEV1)a n d( e x - s m o k e r s
or smoking cessation)” limited to “Humans” and to “All
adults: 19+ years”, from publications cited in Table 2
and 3 of a review by Willemse et al. in 2004 [3], from
the relevant chapter of an International Agency for
Research on Cancer handbook in 2007 [1], from an ear-
lier unpublished collection of literature on smoking and
FEV1 (Alison Thornton, personal communication, 28
October 2004) and from reference lists of papers identi-
fied. Subsequently, on 6 July 2010, the search was
updated to 30 June 2010, with new publications being
identified from this search and from reference lists of
papers identified. Fuller details of the search strategy are
given in Additional file 1 FEV1 search strategy.doc.
Data entry
For each study, relevant data were entered into a study
database and a beta database. The study database con-
tains a single record for each study describing various
study attributes, including relevant publications, sexes
considered, age range, location, timing, length of follow-
up, study design (prospective or intervention study,
study of the general population or of patients with spe-
cified respiratory diseases, nature of the population,
exclusions, study size and use of bronchodilators for
measuring FEV1), availability of FEV1 results (beta, beta
relative to never smokers, beta relative to continuing
smokers and other indices such as beta divided by
height cubed or FEV1 change as a percentage of pre-
dicted), potential confounding variables used for one or
more betas, availability of results for different aspects of
smoking, availability of betas stratified by sex, age and
other stratifying variables, and the number of beta
records in the beta database.
The beta database contains a record for each beta for
each study. This record is divided into four parts. The
first part gives the smoking habits at the start and end
of the follow-up period classified by smoking status
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and nonsmoker), smoking product (any, cigarettes ±
other products, cigarettes only, pipes or cigars only or
pipe only), cigarette type (any, manufactured only or
hand-rolled only) and, where relevant, details of dose-
response variables (measure of exposure and range of
values, for example, 10-19 cigarettes/day). The second
part of the beta record gives the sex and age of the indi-
viduals to whom the beta relates and, where applicable,
details of other stratifying variables (such as baseline
FEV1 level or whether histamine-responsive or not). The
third part gives details of potential confounding vari-
ables taken into account when estimating the beta. The
final part contains the beta data, giving the type of beta
(direct, relative to never smokers or relative to continu-
ing smokers), the value itself expressed as the decline in
millilitres per year (with negative values indicating an
increase) and available information relevant to the varia-
bility of the beta (the lower and upper 95% confidence
interval (CI), standard deviation (SD), standard error
(SE) and number of subjects the beta is based on (N)).
It also contains information on how the beta was
derived and the length of the period studied. Details are
also entered for the reference group for betas relative to
never smokers (never anything, never cigarettes) and for
betas relative to continuing smokers (any product, cigar-
ettes). Commentary also provides further detail relating
to the beta where necessary.
It should be noted that the beta database contains
only data relevant to betas estimated directly relative to
never smokers or relative to continuing smokers. Data
for indices such as FEV1 decline per year divided by
height cubed or percentage change from baseline are
available for very few studies, and data on FEV1 change
as a percentage of predicted, though available for rather
more studies, would have been difficult to use in meta-
analysis because of the varying definition of the pre-
dicted value.
In some studies, the estimate of beta is given directly,
but in others it was estimated by dividing the difference
between FEV1 values given at the start and end of
follow-up by the length of follow-up. The length of fol-
low-up itself was not always provided precisely and
sometimes had to be estimated from information given
on the timing of the relevant surveys. Where necessary,
betas and their SDs or SEs were estimated from data
given graphically or by individual subject.
Fuller details of the variables recorded in the databases
are given in Additional file 2 Data recorded.doc.
Statistical analysis
Most analyses were carried out on the basis of
unweighted and inverse variance-weighted linear multi-
ple regression analysis. For the weighted analysis, an
estimate of SE was required. For some betas, the SE was
given directly, and in others it could be calculated
directly using standard formulae from available informa-
tion on the 95% CI or on N and SD combined. For
some betas, information was available on N, but not on
variability (SD, SE or CI). For those betas, SE was esti-
mated from the age-specific mean SD for those other
betas where the SD was directly available. For some
betas, none of N, SD, SE or CI was provided, so the SE
could not be estimated, the beta not being included in
the weighted analysis. In principle, the SE could have
been estimated from the beta and its associated P value.
However, P values were rarely available, and where pro-
vided they were not given to sufficient accuracy (for
example, only as P < 0.05) to allow reasonable estima-
tion of the SE.
The main analyses were conducted on the four smok-
ing groups already described: never smokers, ex-smokers,
quitters and continuing smokers. Estimates of beta were
n o ti n c l u d e di nt h ea n a l y s i sif information on smoking
habits was lacking at the start or end of follow-up if the
betas related to other smoking groups (for example,
never smokers at the start who smoked during follow-up)
or were for smokers of pipes and/or cigars only. While
multiple betas for the same smoking group and the same
study could be included, provided they were independent
(for example, estimates for different sexes, age groups or
levels of other stratifying variables), only one beta was
chosen from nonindependent alternatives. Where there
was a choice, preference was given to betas based on the
longest follow-up time, betas given separately by age,
betas adjusted for the most variables, betas where the SE
was available or could be calculated, betas based on FEV1
measurements taken without bronchodilator and for
other study-specific reasons described in the Results.
Analyses were carried out using fixed-effects linear
regression models to compare the four smoking groups,
without adjustment for other variables, with adjustment
for both sex (males, females, and sexes combined) and
age (midpoint of age interval in the ranges <40, 40-49,
50-69, and 70+), and with adjustment for “block”,a
block being a set of betas from the same study and for
the same levels of stratifying variables. Data within a
block are presented on the same row in the tables pre-
senting the beta data used in the analyses. The fixed-
effects block-adjusted analyses fit a separate term for
each block. The results of an alternative analysis using a
random effects model in which block effects were
assumed to be normally distributed are also shown.
The relationship of beta to sex, age and various other
factors (length of follow-up period, continental location
of the study, final follow-up year, publication year,
population type and study type) was also studied using
weighted and unweighted fixed-effects linear multiple
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smoking group and the factor of interest. Estimates of
beta with 95% CI are presented by level of smoking
group and factor. Differences between betas for smoking
groups are also presented, with the significance of the
difference presented as P < 0.001, P < 0.01, P <0 . 0 5o r
P ≥ 0.05. For differences between levels of the factors,
only the significance level is presented.
Similar unweighted and inverse variance-weighted lin-
ear multiple regression analyses were also carried out
based on differences in betas within the same block
between (1) continuing smokers and quitters and (2)
continuing smokers and ex-smokers. Whereas the ana-
lyses involving data from all four smoking groups test
whether beta varies by other factors, such as age and
sex, these analyses test whether the specified differences
in beta between smoking groups varies by these factors.
For the purpose of the analysis of differences, the SE of
a difference was estimated as the root mean square of
the SEs of the two betas concerned.
Analyses were also carried out comparing betas by
amount smoked. These were restricted to betas which
concerned continuing smokers, where the unit of expo-
sure was cigarettes/day, where the subject stayed in the
same exposure group between the start and end of fol-
low-up and where preference was given to estimates
adjusted for the most variables. Unweighted and inverse
variance-weighted linear regression analyses related beta
to cigarettes/day after adjustment for block using fixed-
effects modelling. As the data for a given beta were
available only for a range of cigarettes/day smoked, the
value used in the regression analyses was the mean of
the lower and upper limits (for example, mean 19.5
cigarettes/day for 15-24 cigarettes/day). For the highest
consumption groups, which are open-ended, the mean
was estimated assuming that the upper limit was
50 cigarettes/day (for example, mean 37.5 cigarettes/day
for 25+ cigarettes/day).
In interpreting the analyses described above, the most
importance was given to the results from the inverse var-
iance-weighted analyses adjusted for block where rele-
vant using fixed-effects modelling. The unadjusted
analyses and those adjusted for age and sex may be some-
what biased by the fact that the results for the different
smoking groups come from different sets of studies.
Some studies reported betas separately by level of
other factors, each as baseline FEV1, bronchodilator
responsiveness or occupational exposure. To assess
whether beta was associated with the factor, the
unweighted and inverse variance-weighted trends in
beta (increase per level) and their SEs were estimated
separately for continuing smokers, quitters, ex-smokers,
for the difference between quitters and continuing
smokers and for the difference between ex-smokers and
continuing smokers.
The heterogeneity of beta estimates was assessed sepa-
rately for the four smoking groups by an F-test comparing
the between-study variance in betas with the within-study
variance. To avoid complications due to the SE of beta for
some studies having to be calculated indirectly, this assess-
ment was limited to those studies where the SE was pro-
vided or could be calculated from the SD and N and
where N was known.
Software
ROELEE version 3.1 software (available from P.N. Lee
Statistics and Computing Ltd., Sutton, Surrey, UK) was
u s e df o re n t r yo ft h ed a t ai n t ot h es t u d ya n db e t ad a t a -
bases and for virtually all the statistical analyses. The data
were then transferred to SAS version 9.1 software (SAS
Institute Inc., Cary, NC, USA), and the analyses run on
ROELEE were rerun as a cross-check. The analyses treat-
ing block as a random effect were run only in SAS.
Results
The studies
From the abstracts of the publications identified in the
initial search in 2009 and the update in 2010, it was
often possible to tell that no relevant data were avail-
able, and after excluding these publications, a total of
260 were examined in detail, with 96 publications finally
accepted. These publications related to 47 studies. Addi-
tional file 1 FEV1 search strategy.doc, gives fuller details
of the progress of the search, summarized as a flow dia-
gram in Figure 1. Of the 47 studies finally identified,
only 20 were identified directly from the initial MedLine
search in 2009, with a further 11 identified from other
reviews and 15 from secondary references. The updated
search identified only one additional study.
Table 1 summarizes the details of the baseline popula-
tion, exclusions, location and follow-up period of the 47
studies identified, with studies identified in 2009 num-
bered 1 to 46 and the study identified in 2010 numbered
47. Table 2 gives a distribution of various study character-
istics. Thirty-seven studies can be broadly classified as
relating to the general population (though a number of
the studies excluded subjects with specified diseases), with
six relating to subjects with specified respiratory diseases
(or, in the case of study 37, to men with some potential
risk factors for FEV1 decline). Four were intervention stu-
dies, with the presence of a specified respiratory disease
being a requirement for three of these (studies 43, 44 and
46). Twenty-eight studies involved both sexes, and the
remainder involved males only. Fifteen studies were
restricted to relatively young people, with a maximum age
at baseline of 59 years, while three studies were restricted
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Page 4 of 29Medline search 
April 6
th 2009 
514 papers  identified 
415  rejected from examination of abstracts 
99 papers  examined 
34  papers accepted, describing 20 studies 
65  papers rejected (Reason 2: 2, R3: 3, R4 1, R5: 2, R6: 3, 
R7: 10, R8: 2, R9: 3, R10 39) 
11  new papers examined 
9  new papers accepted 
6   new studies identified 
2  new papers rejected (R7: 1, R10: 1) 
From review by 
Willemse et al (2004) 
From review by 
IARC (2007) 
14  new papers examined 
3  new papers accepted 
0  new studies identified 
11  new papers rejected (R1: 4, R5: 1, R6: 1, R7: 4, R10: 1) 
From literature review 
by Thornton 
16  new papers examined 
6  new papers accepted 
5  new studies identified 
10  new papers rejected (R3: 3, R6: 2, R10: 5) 
From secondary references  
of accepted papers 
103  new papers examined 
43  new papers accepted 
15  new studies identified 
60  new papers rejected (R2: 7, R3: 6, R5: 2, R6: 8, R7: 3, 
R8: 2, R9: 2, R10: 30) 
Updating MedLine search 
to June 30
th 2010 
8  new papers examined 
1  new paper accepted 
1  new study identified 
7  new papers rejected (R5: 1, R10: 6) 
Further secondary references  
of newly accepted papers 
9  new papers examined 
0  new papers accepted 
0  new studies identified 
9  new papers rejected (R5: 1, R10: 8) 
Overall summary  260 papers  examined 
96 papers  accepted 
47 studies  identified 
164  papers rejected (R1: 4, R2: 9, R3: 12, R4: 1, R5: 7, R6: 
14, R7: 18, R8: 4, R9: 5, R10: 90) 
Figure 1 Flow diagram for literature search. The diagram shows the number of papers and studies identified, examined, accepted and
rejected at the different stages of the literature search. Reasons for rejection of papers are coded as follows. R1, paper unobtainable; R2, study of
patients with specified conditions that are not chronic obstructive pulmonary disease; R3, study of workers in high-risk occupations; R4, study of
children; R5, review paper with no new studies mentioned; R6, not a prospective study; R7, follow-up period too short (< 2 yr); R8, no follow-up
data; R9, data only for FEV0.75; R10, no relevant data on FEV1 decline in those who gave up smoking. Fuller details are given in Additional file 1
FEV1 search strategy.doc.
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a
Study
no.
References
b Location Follow-up
period
c
Baseline population
d Exclusions
General population studies
1 Bartholomew and Knuiman 1998
[12], James et al. 2005 [13]
Busselton,
Australia
1966-1975
to 1995
9,317 men and women ages 18+
attending health surveys
None
2 Beck et al. 1982 [14] Lebanon, CT,
USA
1972-1978 632 white men and women,
residents of a rural community ages
25+
e
None
3 Bosse et al. 1980 [15], Bosse et al.
1981 [16], Gottlieb et al. 1996 [17],
Sparrow et al. 1983 [18], Sparrow
et al. 1984 [19], Sparrow et al.
1993 [20]
Boston, MA,
USA
1963-1968
to 1978
2,000 male volunteers ages 20-80
(Normative aging study)
Chronic medical conditions
4 Burchfiel et al. 1995 [11] Hawaii, USA 1965-1968
to 1975
4,451 Japanese-American men ages
45-68 (Honolulu Heart Program)
Unacceptable FEV1 measurements
at any time point
5 Burrows et al. 1987 [10],
Camilli et al. 1987 [21]
Tucson, AZ
USA
1972-1973
to 1993
Random sample of 1,705 non-
Mexican-American white men and
women ages 20+
Asthmatic, FEV1 < 60% predicted
6 Chambers et al. 1999 [22] Birmingham,
England
1987-1996 Inner-city general practice study in
117 men and women ages 45-74
None
7 Chinn et al. 2005 [23],
Sunyer et al. 2005 [24]
Western
Europe (26
centres), USA
(1 centre)
1991-1993
to 2002
Random sample of 6,654 men and
women ages 20-44 (European
Community Respiratory Health
Survey)
None
8 Clement and van de Woestijne
1982 [25]
Belgium 1960-1975 2,406 male members of Belgian Air
Force ages 20-45
Less than 3 FEV1 measurements
9 Comstock et al. 1970 [26] USA, four
cities
1962-1963
to 1969
527 male telephone workers ages
40-59
Retired or died by follow-up
10 Corbin et al. 1979 [27] Montreal, QC,
Canada
1971-1976 42 men and women
f ages 29-74,
smokers attending a smoking
cessation clinic, nonsmokers
undefined
FEV1/FVC <70%
11 Eriksson et al. 1985 [28] Malmö,
Sweden
1976-1982 Representative sample of 63 men
age 50
None
12 Ferris et al. 1976 [29] Berlin, NH,
USA
1967-1973 1,156 inhabitants of industrial city,
mainly ages 25-75
g
None
13 Fletcher et al. 1970 [30],
Fletcher et al. 1976 [6],
Fletcher et al. 1977 [31]
London,
England
1961-1969 792 men in engineering works and
clerical workers ages 30-59
Asthmatic, malignant disease, heart
disease, tuberculosis, 50% of
nonsmokers and 20% of smokers
without persistent phlegm or chest
illness
14 Frew et al. (1992) [32] Vancouver, BC,
Canada
1981-1983
to 1989
733 men ages 15+; grain workers,
sawmill workers and office workers
Significant medical disorders or
FEV1 < 1.5 L or severe asthma
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a (Continued)
15 Górecka and Czernicka-Cierpisz
1992 [33]
Warsaw,
Poland
1987-1991 116 male and female hospital
workers ages 19-71
h
No direct contact with patients
16 Griffith et al. 2001 [34] USA, 4
communities
1989-1993
to 1996
5242 men and women ages 65+
(Cardiovascular Health Study of
older adults)
Could not give informed consent,
terminally ill, institutionalized,
unable to walk, likely to move in
next 3 years
17 Huhti and Ikkala 1980 [35] Harjavalta,
Finland
1961-1971 1,037 men and women in rural
population ages 40-64
Pulmonary tuberculosis, clinically
significant respiratory disease (other
than asthma or emphysema)
18 Humerfelt et al. 1993 [36] Bergen,
Norway
1965-1970
to 1990
Random sample of 951 men ages
22-54
None
19 Katoh et al. 2001 [37] K-town, Japan 1985-1988
to 2000
1,596 men and women ages 39+ Ever had asthma
20 Kauffman et al. 1979 [38],
Kauffman et al. 1979 [39],
Kauffman et al. 1997 [40]
Paris area,
France
1960-1961
to 1972
575 working men ages 30-54 Incorrect spirographs at either
survey
21 Krzyzanowski et al. 1986 [41] Cracow,
Poland
1968-1981 Random sample of 1,824 male and
female residents ages 19-70
None
22 Lange et al. 1989 [42], Vestbo and
Lange 1994 [43]
Copenhagen,
Denmark
1976-1978
to 1983
Random sample of 7,764 men and
women ages 20+ from area around
hospital (Copenhagen City Heart
Study)
Asthmatic, smoked tobacco
products other than cigarettes, quit
<1 year before end
23 Taylor et al. 1985 [44], Lim et al.
1988 [45], Watson et al. 1993 [46],
Watson et al. 2000 [47]
West London,
England
1974-1997 227 men ages 20-54 recruited from
local employers, supplemented by
sample of heavy smokers used in
earlier studies
Asthmatic, chest illness, abnormal
X-ray
24 Liu and Wang 1999 [48] Beijing, China 1987-1997 63 men and women
f ages 60+ Abnormal physical examination,
ECG or X-ray; FVC ≤80% of pretest;
FEV1 ≤75% of pretest; FEV1/FVC
≤75%
25 Olofsson et al. 1986 [49] Gothenburg,
Sweden
1973-1980 460 men born in 1913 (age 60) or
in 1923 (age 50)
None
26 Omori et al. 2005 [50] Kumamoto,
Japan
1994-1999 1,888 men ages 35-74 attending
medical checkup
Asthmatic, other pulmonary
disease, X-ray abnormalities, quit
smoking before baseline
27 Sandvik et al. 1995 [51] Oslo, Norway 1972-1975
to 1982
1,393 healthy men ages 40-59
working in 5 companies
Heart disease, stroke, cancer,
diabetes, hypertension and other
miscellaneous diseases
28 Sato et al. 1997 [52] Niita City,
Japan
1983-1986
to 1989
429 “healthy” male office workers
ages 15-65
Heart or lung disease
29 Sherman et al. 1992 [53], Xu et al.
1992 [54]
USA, 6 cities 1974-1976
to 1988
Random sample of 8,191 men and
women ages 25-74 (Six Cities
Study)
None
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a (Continued)
30 Soejima et al. 2000 [55] Tokyo, Japan 1991-1994
to 1999
83 men and women ages 35-83
attending Keio University Hospital
Lung cancer, marked lung
abnormalities
31 Tashkin et al. 1984 [56],
Tashkin et al. 1994 [57]
Los Angeles,
CA, USA
1973-1978
to 1982
2,401 men and women ages 25-64
in 4 areas varying by pollution level
Nonwhites, inconsistent
demographics
32 Van der Lende et al. 1981 [58], Xu
et al. 1994 [4],
Rijcken et al. 1995 [5]
Vlagtwedde
and
Vlaardingen,
Netherlands
1965-1969
to 1990
4,692 men and women ages 15-54
in a rural area and a polluted area
None
33 Villar et al. 1995 [59] Southampton,
England
1987-1988
to 1992
198 men and women ages 65+
randomly selected from 3 general
practices
None
34 Vollmer et al. 1985 [60] Portland, OR,
USA
1974-1983 Random sample of 48 men and
women ages 25-54 from
Multnomah County
None
35 Vollmer et al. 1985 [60] Portland, OR,
USA
1971-1972
to 1982
128 men and women ages 34-83
h
volunteering for lung function
testing
Abnormal FEV1
36 Wilhelmsen et al. 1969 [61] Gothenburg,
Sweden
1963-1967 313 men born in 1913 (age 50) None
47 Kohansal et al. 2009 [62] Framingham,
MA, USA
1971-1975
to 1977
4,391 men and women ages 13-71
(Framingham Offspring Cohort)
None
Studies of patients with specific
diseases
37 Annesi et al. 1992 [63] Paris, France 1980-1981
to 1986
310 male policemen ages 22-55
with some potential risk factors for
FEV1 decline
i
None
38 Demedts 1988 [64] Leuven,
Belgium
1975-1985 13 male patients ages 41-63 with
early emphysema
j
None
39 Grol et al. 1999 [65] Groningen,
Netherlands
1983-1986
to 1996
95 men and women ages 21-33
identified as having allergic asthma
when assessed at ages 5-14
Other specific respiratory diseases,
for example, cystic fibrosis or
tuberculosis
40 Howard 1974 [66] Sheffield,
England
1966-1972 144 men and women ages 42-78
h
with obstructive airway disease
Ischaemic and rheumatic heart
disease, severe physical deformity
41 Hughes et al. 1982 [67] London,
England
1966-1976
to 1979
56 men ages 39-71
h with
emphysema and vascular
attenuation or destruction
Other severe lung diseases or
abnormalities, thoracic surgery, a1-
antitrypsin deficiency
k
42 Postma et al. 1986 [68] Groningen,
Netherlands
1964-1972
to 1985
81 nonallergic men and women
ages 30-66
h with chronic airflow
obstruction and considerable lung
function impairment
l
Other progressive or life-
threatening disease, used
corticosteroids for >9 months
Intervention studies
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Page 8 of 29to relatively older adults, with a minimum age at baseline
of at least 60 years. Of the 44 single-country studies, 13
were conducted in the USA, 2 in Canada, 6 in the UK, 7
in Western Europe, 7 in Scandinavia, 2 in Eastern Europe,
6 in Asia and 1 in Australia. There were also three multi-
country studies (studies 7, 43 and 44). Many of the studies
started many years ago: 16 began in 1960-1969 and 15
began in 1970-1979. On the basis of the difference
between the year of start at baseline and the year of the
end of follow-up, the mean length of follow-up is
estimated as 11 years, with seven studies taking at least
20 years. An attempt was made to determine, for each
study, the number of individuals entering the follow-up
period. This ranged from a minimum of 13 individuals in
study 38 to 9,317 individuals in study 1. Twenty-one stu-
dies included at least 1,000 individuals.
Estimates of FEV1 decline by smoking habit ("betas”)
From the 47 selected studies, 951 beta estimates were
derived. A total of 849 are direct estimates for specified
Table 1 Details of studies providing data on FEV1 decline in people who gave up smoking
a (Continued)
43 Anthonisen et al. 1994 [7], Scanlon
et al. 2000 [69], Kanner et al. 2001
[70], Anthonisen et al. 2002 [71]
USA and
Canada, 10
centres
1986-1989
to 2000
5,887 men and women ages 35-60
with mild to moderate COPD
m who
smoked 10+ cigarettes/day within
30 days of screening (Lung Health
Study). The subjects were randomly
allocated to 3 groups: SIA = special
intervention smoking cessation
programme plus ipratropium
bromide inhaler, SIP = special
intervention smoking cessation
programme plus placebo inhaler,
UC = usual care group
Serious illness, pregnant, used
physician-prescribed
bronchodilators, b-adrenergic
antagonists or systemic
glucocorticoids or admitted 25+
drinks/week
44 Soriano et al. 2007 [72] USA and
Europe, 7 trials
Dates not
given; 12-
to 36-
month
follow-up
period
1,901 men and women in placebo
groups of pooled data from 7
randomized trials of inhaled
corticosteroids versus placebo in
patients with moderate to severe
COPD
Asthmatic, ex-smokers (in one of
the 7 trials)
45 Townsend 1987 [73],
Townsend et al. 1991 [74]
USA, 22
centres
1973-1974
to 1982
4,926 men ages 35-57 free of heart
disease but at high risk based on
their blood pressure, serum
cholesterol level and cigarette
smoking (MRFIT study). The subjects
were randomly allocated to 2
groups: SI = special intervention on
smoking, diet and antihypertensive
medication; UC = usual care
Very high blood pressure or
cholesterol, used b-blockers, serious
life-threatening disease, believed
unable to participate, smoked
cigars, cigarettes or pipes, FEV1
measured for <2 years in latter half
of follow-up
46 Xie et al. 2001 [75] China, 3
provinces
1992-2000 869 men and women ages 15+
living in rural areas with chronic
respiratory symptoms
n and FEV1/
FVC ≥ 70%. The areas were
randomly allocated to intervention,
involving establishment or an
organization towards improving
medical services, promoting
smoking cessation and supplying
targeted pharmaceutical treatment,
and control.
None
aFEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ECG, electrocardiogram; COPD, chronic obstructive pulmonary disease; MRFIT study,
Multiple Risk Factor Intervention Trial.
bOnly references to publications providing relevant data are shown. On occasion, additional publications were used to
obtain further study details.
cThe range of years for the baseline evaluation is shown followed by the last year at which follow-up occurred.
dThe numbers of
subjects given are generally numbers followed up. The age range is sometimes estimated approximately from the mean, standard error/deviation and sample
size.
eSubjects in the age range 7-24 are also included in the study, but the results are not used.
fIt is assumed that subjects of both sexes were included, though
this is not stated in the paper.
gSome older subjects previously studied in 1961 were also included.
hThe age range is approximate, estimated from the mean,
standard error/deviation and sample size.
iThe potential risk factors for FEV1 decline("beta”) include a history of asthma, wheezing, any perceived
hyperresponsiveness symptom, eczema, urticaria, bronchopneumonia before age 2, eosinophilia (among nonsmokers) and heterozygous Z mutation of the a1-
antitrypsin gene (PiMZ) phenotype.
jDiagnosed on the basis of a decrease in single-breath diffusing capacity and in elastic lung recoil with hyperinflation and
only minor airway obstruction, and with compatible chest X-ray film changes.
kHomozygous for Pi type Z a1-antitrypsin deficiency or heterozygous for SZ type
a1-antitrypsin deficiency.
lFEV1/FVC 40% to 55% and increasing <15% after bronchodilator.
mFEV1/FVC ≤70% (screen 2) and ≤75% (screen 3), and FEV1
percentage predicted 55% to 90% (screen 2) and 50% to 90% (screen 3).
nCough and/or expectoration for 2+ years for 3+ mo/yr.
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Page 9 of 29smoking groups, 12 are estimates expressed relative to con-
tinuing smokers and 90 are estimates expressed relative to
never smokers. For the purposes of this publication, atten-
tion is restricted to the direct estimates. This is partly
because the number of direct estimates is much larger and
partly because both the studies providing data relative to
continuing smokers and 8 of 10 studies providing data
relative to never smokers also provide direct estimates of
betas. Also, though the estimates relative to never smokers
can be used to estimate differences in betas between conti-
n u i n gs m o k e r sa n dt h o s ew h og a v eu ps m o k i n g( o u rm a j o r
interest), it was not possible to estimate SDs because of the
nonindependence of the betas for the two smoking groups
arising from the common comparison group.
The analyses conducted are either unweighted or
i n v e r s ev a r i a n c e - w e i g h t e d .F o rab e t at ob ei n c l u d e di n
the weighted analyses, an estimate of its SE is required.
This information is available directly for 173 of the 849
betas and can readily be calculated from SD and N for
205 and from the 95% CI for 44. While it was not possi-
ble to derive an estimate for 154 betas, an estimate of
SE was imputed for 273 betas where only N was avail-
able using age-specific estimates of SD (52.75 for age
<40, 52.11 for age 40-49, 48.97 for age 50-69 and 26.61
Table 2 Distribution of study characteristics
Characteristic Level No. of studies (%) Characteristic Level No. of studies (%)
Sex Both 28 (59.6) Year at end
a 1960-69 3 (6.4)
Males only 19 (40.4) 1970-79 10 (21.3)
1980-89 15 (31.9)
Lowest age 13-29 23 (48.9) 1990-99 14 (29.8)
30-39 10 (21.3) 2000+ 4 (8.5)
40-49 8 (17.0) Not known
b 1 (2.1)
50-59 3 (6.4)
60+ 3 (6.4) Follow-up (yr) 4-9 23 (48.9)
10-14 13 (27.7)
Highest age
c < 50 3 (6.4) 15-19 3 (6.4)
50-59 12 (25.5) 20+ 7 (14.9)
60-69 8 (17.0) Not known
b 1 (2.1)
70+ 24 (51.0)
Study type Cohort 43 (91.5)
Country USA 13 (27.7) Intervention 4 (8.5)
Canada 2 (4.3)
UK 6 (12.8) Population General 37 (78.7)
France 2 (4.3) Diseased
d 10 (21.3)
Belgium 2 (4.3)
Netherlands 3 (6.4) Medical exclusions Some 25 (53.2)
Sweden 3 (6.4) None 22 (46.8)
Norway 2 (4.3)
Denmark 1 (2.1) Subjects (at start) 13-100 9 (19.1)
Finland 1 (2.1) 101-500 10 (21.3)
Poland 2 (4.3) 501-1,000 7 (14.9)
Japan 4 (8.5) 1,001-5,000 15 (31.9)
China 2 (4.3) > 5,000 6 (12.8)
Australia 1 (2.1)
Multicountry 3 (6.4) Betas adjusted None 29 (61.7)
Some 18 (38.3)
Year at start 1960-69 16 (34.0)
1970-79 15 (31.9)
1980-89 11 (23.4)
1990-99 4 (8.5)
Not known
b 1 (2.1)
aYear at end of follow-up.
bStudy 44 gave no information on timing, but since it was published in 2007 and involved follow-up of at most 3 years, it seems likely
to have been conducted recently.
cAt baseline.
dAll four intervention studies comprised patients with specified medical conditions.
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vide an estimate of SD.
Selection of betas for the main analyses comparing the
four smoking groups
Of the 849 direct estimates, 97 were not considered for
further analysis, as information on smoking habits was
unavailable at baseline for 4 betas and at the end of fol-
low-up for 93. Of the remaining 752 estimates, 684
relate to the major smoking groups: never smokers, ex-
smokers, quitters and continuing smokers, with the
remaining 68 relating to rarer or less clearly defined
combinations of smoking habits, such as those who
were never smokers at baseline and current smokers at
follow-up or those who were current smokers at base-
line and ever smokers at follow-up.
A further 173 betas were also rejected from the main
analysis: 166 because they were dose-response estimates
(considered separately) and 7 because the smokers were
smokers of pipes and/or cigars only. This left 511 poten-
tially useful estimates.
To avoid double-counting of nonindependent data,
there was a need in certain studies for a decision to be
made regarding which estimates to include in our main
analysis and which to exclude. In studies 41 and 43, pre-
ference is given to betas on the basis of measurements
taken without use of a bronchodilator, as this applies to
most of the available data. Preference is also given to
betas based on the longest available follow-up time
(relevant to studies 1, 4 and 23), betas given separately
by age (studies 4 and 25), betas that are adjusted for the
most variables (studies 3, 13 and 46), betas from publi-
cations that provide information for all four smoking
groups (studies 5, 23, 29, 31 and 45) and betas with
information on N, SD or SE (study 7). Also, for study
32, preference is given to the unstratified data from the
1994 paper [4] for quitters and to the data stratified by
airway responsiveness from the 1995 paper [5] for the
other smoking groups, as the later source did not give
data for quitters. For study 47, preference is given to the
data unstratified for healthy versus unhealthy status, as
stratified results were available only for current smokers.
The betas and SEs used in the main analyses are
shown in Table 3. These relate to only 39 of the 47
studies, with two studies (8 and 33) providing only esti-
mates relative to never smokers and six studies (11, 14-
16, 24 and 40) having incomplete information on smok-
ing habits. For some studies, data are not available for
all four smoking groups, notably for study 25, where
only data for never smokers are available, data for conti-
nuing smokers being classified by amount smoked and
for those who gave up being for ex-smokers and quitters
combined. Studies 37, 46 and 47 also have data only for
ex-smokers and quitters combined. It should be noted
that for study 29, the age-specific data which have
no SEs are used in the unweighted analyses, but the
ages combined data, which do have SEs, are used in
the weighted analyses. SEs are available for all other
estimates except for those for never smokers and ex-
smokers in study 45. There are a total of 303 estimates
of beta in Table 3 with 295 being available for
unweighted analyses (all except the eight estimates for
ages 25-74 for study 29) and 261 being available for
weighted analyses (all except the 40 estimates in study
29 and the 2 estimates in study 45 without SEs).
Comparison of betas in the four smoking groups
Table 4 compares betas in the four smoking groups based
on unweighted and inverse variance-weighted analysis.
The results are shown without adjustment, with adjust-
ment for age and sex and with adjustment for block. Each
row of data in Table 3 is a block, and the block-adjusted
analysis attempts to adjust simultaneously for all the fac-
tors fixed in the study design and by the choice of sub-
group for analysis. Adjustment for age and sex reduces the
residual variance by 27.4% in the unweighted analysis and
by 30.6% in the weighted analysis, while adjustment for
block reduced it by 76.9% in the unweighted analysis and
by 78.1% in the weighted analysis.
The results consistently show a lower beta in never
s m o k e r st h a ni nc o n t i n u i n gs m o k e r s( P < 0.001) with
the difference estimated as 10.8 mL/yr (95% CI, 8.9 to
12.8) in the weighted, block-adjusted analysis and over
10 mL/yr in all the other analyses. Ex-smokers also
show a beta that is consistently less than that in conti-
nuing smokers (P <0 . 0 0 1i na l la n a l y s e s ) ,w i t ht h ee s t i -
mated difference (12.4 mL/yr; 95% CI, 10.1 to 14.7, in
the weighted, block-adjusted analysis) again always over
10 mL/yr. Betas for ex-smokers and never smokers do
not vary significantly in any of the analyses. Betas for
quitters lie between those for continuing smokers and
never smokers in all the analyses, consistent with the
quitters’ having smoked for only part of the follow-up
period. In the weighted, block-adjusted analysis, beta is
estimated to be 8.5 mL/yr (95% CI, 5.6 to 11.4) less in
quitters than in continuing smokers (P < 0.001) and
2.4 mL/yr (95% CI, -0.4 to 5.1) more in quitters than in
never smokers.
In the text above, the block-adjusted results cited are
those based on fixed-effects modelling. As is evident
from Table 4 the alternative analyses using random-
effects modelling produced virtually identical beta esti-
mates to those using fixed-effects modelling. Though
the CIs using random-effects modelling are somewhat
wider, the interpretation of the data is unaffected, with
betas for continuing smokers clearly greater (P <0 . 0 0 1 )
than those in the other three groups, which do not dif-
fer significantly.
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Page 11 of 29Table 3 Data on FEV1 decline selected for main analyses
Stratifying variables Follow-up
(yr)
No. of
adjusted
Beta (SE)
d
Study
no.
Reference
Sex
Age
range
a Other
b variables
c
Never
e
smokers
Ex-
smokers
f Quitters
g
Continuing
smokers
h
1 Bartholomew and
Knuiman [12]
M 19-44 - 6 2 36.8 (6.2) 14.0
(11.2)
54.7 (7.1)
M 45+ - 6 2 45.8 (6.4) 51.2 (7.9) 60.5 (6.5)
F 19-44 - 6 2 24.3 (6.6) -15.3
(11.3)
13.7 (10.8)
F 45+ - 6 2 30.7 (4.7) 35.2 (7.4) 46.5 (10.3)
2 Beck et al. [14] M 25-34 - 6 0 -20.7 (9.5) 0.8 (12.1) -3.0 (9.8)
M 35-44 - 6 0 2.5 (15.0) -14.3 (8.8) 19.5 (9.1)
M 45+ - 6 0 20.0 (4.9) 31.0 (3.4) 25.5 (5.3)
F 25-34 - 6 0 -8.5 (6.9) -32.5
(11.5)
15.2 (8.3)
F 35-44 - 6 0 18.8 (7.5) 13.5 (12.0) 20.8 (8.6)
F 45+ - 6 0 10.3 (2.9) 10.7 (5.0) 32.0 (5.8)
3 Bossé et al. [16] M 20-34 - 5 1 23.0 (9.0) 24.0
(11.0)
57.0 (8.0)
M 35-42 - 5 1 47.0 (7.0) 61.0
(12.0)
76.0 (6.0)
M 43-80 - 5 1 82.0 (7.0) 73.0 (9.0) 101.0 (7.0)
4 Burchfiel et al. [11] M 45-49 - 6 1 19.5 (2.9) 19.8 (3.1) 21.2 (4.9) 31.3 (2.4)
M 50-59 - 6 1 21.6 (1.8) 21.5 (2.0) 28.3 (3.3) 32.4 (1.8)
M 60-68 - 6 1 25.0 (3.2) 26.0 (3.4) 35.1 (6.1) 40.1 (3.5)
5 Camilli et al. [21] M 20-34 - 9.4 0 1.0 (6.1) -9.0 (15.2) -22.0
(12.4)
6.0 (7.2)
M 35-49 - 9.4 0 9.0 (8.3) 1.0 (9.8) 12.0
(13.5)
18.0 (7.6)
M 50-69 - 9.4 0 19.0 (7.1) 24.0 (5.4) 34.0
(10.0)
40.0 (5.8)
M 70+ - 9.4 0 25.0 (3.8) 26.0 (3.2) 37.0 (7.7) 26.0 (7.7)
F 20-34 - 9.4 0 -5.0 (5.5) -18.0
(13.2)
-27.0
(14.1)
-4.0 (8.0)
F 35-49 - 9.4 0 6.0 (6.5) 4.0 (9.1) 7.0 (17.4) 12.0 (7.4)
F 50-69 - 9.4 0 13.0 (3.9) 15.0 (5.8) 17.0 (9.1) 21.0 (5.0)
F 70+ - 9.4 0 21.0 (2.1) 20.0 (4.6) 25.0 (7.7) 26.0 (6.1)
6 Chambers et al. [22] M
+F
45-74 - 9 0 43.5 (4.4) 47.3 (6.4) 41.1
(19.3)
52.0 (4.4)
7 Chinn et al. [23] M 20-44 - 8 0 32.0 (1.1) 31.0 (1.6) 31.0 (2.1) 35.0 (1.4)
F 20-44 - 8 0 24.0 (0.7) 27.0 (1.2) 22.0 (1.8) 27.0 (1.1)
9 Comstock et al. [26] M 40-59 - 5.25 0 32.4 (7.1) 78.1 (3.1)
10 Corbin et al. [27] M
+F
29-74
i -4
j 0 -8.6 (15.0) 35.0
(16.3)
20.0 (11.4)
12 Ferris et al. [29] M 25-74 - 6 2 -10.0 (4.9) -6.7 (4.5)
F 25-74 - 6 2 -8.3 (2.6) 0.0 (7.2)
13 Fletcher et al. [6] M 30-59 F1 8 4 36.0 (9.0) 34.0 (6.0) 37.0
(11.0)
60.5 (2.2)
M 30-59 F2 8 4 45.0 (6.0) 36.0 (5.0) 47.0
(11.0)
47.6 (2.3)
M 30-59 F3 8 4 33.0 (3.0) 26.0 (4.0) 26.0
(14.0)
40.4 (2.2)
17 Huhti et al. [76] M 40-64 - 10 0 33.0 (3.4) 45.0 (3.1) 44.0 (4.0) 51.0 (2.4)
F 40-64 - 10 0 27.0 (1.0) 27.0 (4.7) 39.0 (6.9) 35.0 (3.5)
18 Humerfelt et al. [36] M 22-54 - 23 0 46.6 (1.4) 47.0 (1.3) 51.5 (1.1)
19 Katoh et al. [37] M 39+ - 12 0 30.0 (1.9) 31.7 (1.8) 37.9 (2.1) 39.2 (1.5)
F 39+ - 12 0 20.8 (0.5) 21.7 (2.5) 16.7 (5.2) 30.8 (4.2)
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20 Kauffmann et al. [39,40] M 30-54 - 12 2
k 40.8 (4.8) 49.4 (4.1) 46.1 (1.6)
21 Krzyzanowski et al. [41] M 19-70 - 13 2 47.3 (4.1) 50.4 (5.3) 66.5 (4.4) 59.7 (2.6)
F 19-70 - 13 2 38.3 (1.9) 30.1 (9.6) 37.3 (6.9) 42.0 (3.6)
22 Lange et al. [42] M 20-54 - 5 0 21.0 (7.0) 27.0 (7.0)
M 55+ - 5 0 34.0 (9.0) 36.0 (5.0)
F 20-54 - 5 0 13.0 (3.0) 18.0 (5.0)
F 55+ - 5 0 32.0 (3.0) 32.0 (4.0)
23 Watson et al. [47] M 20-54 - 22 0 34.2 (2.2) 33.1 (2.8) 38.8 (3.3) 51.0 (4.0)
25 Olofsson et al. [49] M 50 - 7 0 54.3 (8.5)
M 60 - 7 0 57.1 (6.3)
26 Omori et al. [50] M 35-44 - 5 0 32.8 (8.3) 38.8 (6.1) 33.7 (4.0)
M 45-54 - 5 0 31.9 (2.9) 35.3 (2.7) 44.5 (2.1)
M 55-64 - 5 0 31.3 (2.9) 35.4 (2.7) 38.9 (2.7)
M 65-74 - 5 0 33.9 (3.1) 30.4 (4.2) 43.1 (4.5)
27 Sandvik et al. [51] M 40-49 - 7
l 0 10.3 (6.4) 31.7 (4.3)
M 50-59 - 7
l 0 27.4 (4.8) 45.4 (4.8)
28 Sato et al. [52] M 15-65
m - 3 0 2.0 (12.4) 18.0 (16.9) 36.0 (7.9)
29 Xu et al. [54] M 25-34 - 6 1 15.2 6.4 -6.2 34.2
M 35-44 - 6 1 24.9 23.9 47.4 34.5
M 45-54 - 6 1 41.9 39.4 32.2 63.8
M 55-64 - 6 1 45.9 43.2 66.7 60.4
M 65-78 - 6 1 55.6 52.3 60.2 63.3
M 25-74 - 6 2 37.8 (2.0) 34.3 (1.8) 41.2 (5.0) 52.9 (2.0)
F 25-34 - 6 1 13.8 13.9 -7.4 22.2
F 35-44 - 6 1 25.0 29.8 6.2 34.9
F 45-54 - 6 1 30.4 26.0 31.7 40.1
F 55-64 - 6 1 34.1 40.6 38.9 48.3
F 65-78 - 6 1 39.2 34.9 70.1 38.2
F 25-74 - 6 2 29.0 (0.9) 29.6 (1.6) 28.7 (4.3) 38.0 (1.2)
30 Soejima et al. [55] M
+F
35-83
n - 5 0 20.0 (1.7) 30.0 (8.7) 60.0 (3.4)
31 Tashkin et al. [56] M 25-64 - 5 3 56.0 (2.6) 52.0 (3.0) 62.0 (5.1) 70.0 (3.1)
F 25-64 - 5 3 42.0 (1.9) 38.0 (2.8) 38.0 (6.6) 54.0 (4.0)
32 Xu et al. [4] M 25-54 - 24 0 6.1 (7.2)
F 25-54 - 24 0 2.7 (6.1)
Rijcken et al. [5] M 25-54 H0 24 1 30.8 (9.8) 28.5 (5.0) 37.1 (4.5)
F 25-54 H0 24 1 24.9 (3.9) 24.7 (7.2) 27.3 (5.1)
M 25-54 H1 24 1 41.2 (17.0) 33.0 (8.0) 40.3 (6.5)
F 25-54 H1 24 1 25.3 (6.0) 30.6 (9.6) 33.1 (6.4)
34 Vollmer et al. [60] M
+F
25-54 B1 9 0 38.0 (52.1) 89.0
(19.7)
67.0 (26.1)
M
+F
25-54 B0 9 0 43.0 (30.1) 43.0
(11.4)
45.0 (15.0)
35 Vollmer et al. [60] M
+F
34-83 B1 11 0 49.0 (18.5) 70.0
(17.3)
70.0 (11.9)
M
+F
34-83 B0 11 0 37.0 (10.7) 56.0
(10.0)
60.0 (6.9)
36 Wilhelmsen et al. [61] M 50 - 4 0 40.0
(16.8)
73.2 (7.1)
37 Annesi et al. [63] M 22-55 I1 5 0 31.7 (5.9) 51.7 (5.8)
M 22-55 I2 5 0 59.7 (9.8) 32.7 (8.8)
38 Demedts [64] M 41-63
o - 10 0 72.5 (37.5) 88.8
(21.4)
98.4 (10.8)
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adjusted analyses (fixed effects or random effects) which
w e r er u ne x c l u d i n gt h o s eb e t a sw h e r eo n l yb e t aa n dN were
available, and the SE was imputed from age-specific esti-
mates of SD derived from other studies (data not shown).
Two sets of additional analyses corresponding to those
in Table 4 but differing in the betas included, were also
conducted. The additional weighted analyses were based
on those 253 betas used in the unweighted analyses pre-
sented in Table 4 that had SEs, and the additional
unweighted analyses were based on the 261 betas used
in the weighted analyses in Table 4. The results (not
shown) were very similar to those shown in Table 4
with mean betas lowest (and similar) in never smokers
and ex-smokers, highest in continuing smokers and
intermediate in quitters.
Heterogeneity of betas
The ratio of between-study to within-study variance in
betas was estimated as 11.94 for never smokers (P <
0.001), 15.51 for continuing smokers (P < 0.001), 9.84
for quitters (P < 0.01) and 1.32 (NS) for ex-smokers.
These ratios were based on, respectively, those 28, 30,
27 and 24 beta estimates considered in the main ana-
lyses for which information was available on N and also
either SE or SD.
Relationship of beta to age, sex and study characteristics
T a b l e5g i v e st h er e s u l t so fa n a l y s e sr e l a t i n gb e t at o
age, sex and various study characteristics. Note that as
some betas were for the sexes combined, the para-
meter of sex has three levels (males, females, and
both). In the inverse variance-weighted analysis, betas
are clearly lower in females (compared to both males
and the sexes combined) and are lower at age <40
years and age 70+ years than at ages 40-49 and 50-59
years. After adjustment for age, sex and smoking
group, no significant association is seen with popula-
tion type or study type. There is evidence that betas
are somewhat greater in studies in Europe than in
Table 3 Data on FEV1 decline selected for main analyses (Continued)
39 Grol et al. [65] M
+F
21-33 - 11 0 19.7 (8.0) -26.4
(23.6)
23.4 (11.5)
41 Hughes et al. [67] M 44-69 - 8 0 16.4 (8.8)
42 Postma et al. [68] M
+F
30-66 - 11 0 49.0 (7.0) 85.0 (5.1)
43 Kanner et al. [70]
p M
+F
35-60 D1 5 0 13.1 (1.8) 55.9 (1.0)
M
+F
35-60 D2 5 0 27.6 (5.7) 58.5 (3.0)
M
+F
35-60 D3 5 0 24.0 (7.8) 63.4 (3.0)
M
+F
35-60 D4 5 0 20.3 (8.7) 66.4 (3.7)
M
+F
35-60 D5 5 0 12.0 (11.9) 69.4 (4.7)
44 Soriano et al. [72]
q M 40+ - 1.5 1 16.0 (2.7) 21.3 (2.0)
F 40+ - 1.5 1 11.3 (4.3) 16.7 (2.0)
45 Townsend [73]
p M 35-57 - 7 0 39.5 40.0 40.0 (4.7) 62.3 (2.8)
46 Xie et al. [75]
p M
+F
15+ - 8 5 39.5 (3.3) 37.3 (2.2)
47 Kohansal et al. [62] M 13-71 - 23 0 19.6 (1.3) 38.2 (2.2)
F 13-71 - 23 0 17.6 (1.9) 23.9 (1.6)
aExcept where noted, age range applies to results for each smoking group.
bOther stratifying variables are indicated as follows: F1, F2, F3 = forced expiratory
volume in 1 second (FEV1) at baseline <55, 55-64, 65+ cL/m
3 H0, H1 = histamine responsiveness (no or yes); B0, B1 = bronchodilator responsiveness (no or yes);
I1, I2 = immunoglobulin E level ≤100, 100+ IU/mL; D1, D2, D3, D4, D5 = doctor visits for lower respiratory illnesses 0-0.24, 0.25-0.49, 0.50-0.99, 1.00-1.49, or 1.50+
per year.
cNumber of adjustment variables. The variables considered by study are 1: age, change in body mass index; 3: baseline FEV1; 4: height; 12: height; 13:
age, height, season, and observer; 29: age (only for age group 25-74), height; 31: age, height, area; 32: height; 46: sex, age, height, region, family history of
chronic obstructive pulmonary disease (COPD).
dBeta = Decline in FEV1 (in mL/yr) over follow-up period. Results are not postbronchodilator measurements,
except for study 44. For studies 9, 22 and 38, smoking is of cigarettes only. For studies 2, 3, 12, 23, 26, 29, 31 and 43, smoking is of cigarettes regardless of other
products. For study 13, current smoking is of cigarettes regardless of other products, but giving up smoking is of any product. For other studies, smoking relates
to any tobacco product.
eNever smoked by end of follow-up.
fGave up smoking before baseline and did not resume smoking.
gSmoked at baseline, but not at
end of follow-up.
hSmoked at baseline and at end of follow-up.
iAge range varies by smoking group: Never smokers 30-65, quitters 30-74 and continuing
smokers 29-60.
jFollow-up period is 3.5 years for never smokers.
kOnly results for quitters and continuing smokers were adjusted.
lFollow-up period is 7.6 years
for quitters and 7.1 years for continuing smokers.
mAge range varies by smoking group: Never smokers 15-60, ex-smokers 26-64 and continuing smokers 21-61.
nAge range varies by smoking group: Never smokers 32-80, ex-smokers 29-91, continuing smokers 38-78.
oAge range varies by smoking group: Never smokers
44-51, ex-smokers 42-63 and continuing smokers 41-53.
pResults are based on all groups combined in the intervention study.
qResults are based only on usual
care group and are postbronchodilator measurements.
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Page 14 of 29North America and in studies where the final follow-
up year and publication year were 1980 or later. In the
unweighted analyses, there are again associations with
age, sex, continental location of study and final follow-
up year, but the association with publication year is no
longer significant.
Although Table 5 provides evidence of variation in
beta by sex, age and other study characteristics, it was
clear from inspection of the SDs in the various regres-
sion models that none of these characteristics could
explain more than a small part of the between-study
heterogeneity noted above (data not shown).
Table 4 FEV1 decline (in mL/yr) by smoking group
a
Never smokers
b
(95% CI)
Ex-smokers
c
(95% CI)
Quitters
d
(95% CI)
Continuing smokers
e
(95% CI)
Unweighted analysis
f
Number of betas 80 66 64 85
Unadjusted Mean 27.9 (23.5-32.4) 24.1 (19.2-29.1) 33.4 (28.4-38.4) 42.8 (38.5-47.2)
Diff 1 -14.9*** -18.7*** -9.4** Base
Diff 2 Base -3.8
NS +5.5
NS +14.9***
Adjusted for age and sex Mean 28.8 (25.0-32.7) 24.6(20.3-28.8) 33.0 (28.7-37.3) 41.9 (38.2-45.6)
Diff 1 -13.1*** -17.4*** -8.9** Base
Diff 2 Base -4.3
NS +4.2
NS +13.1***
Adjusted for block
g
(fixed-effects model) Mean 28.7 (26.4-30.9) 27.0 (24.5-29.5) 30.4 (27.9-33.0) 42.1 (40.0-44.3)
Diff 1 -13.5*** -15.2*** -11.7*** Base
Diff 2 Base -1.7
NS +1.7
NS +13.5***
(random-effects model) Mean 28.6 (24.4-32.9) 26.6 (22.2-31.0) 30.6 (26.2-35.1) 42.2 (38.0-46.4)
Diff 1 -13.6*** -15.6*** -11.6*** Base
Diff 2 Base -2.1
NS +2.0
NS +13.6***
Weighted analysis
h
Number of betas 71 57 56 77
Unadjusted Mean 26.1 (23.9-28.3) 29.3 (25.6-32.9) 38.3 (33.5-43.2) 41.8 (39.1-44.6)
Diff 1 -15.7*** -12.6*** -3.5
NS Base
Diff 2 Base +3.1
NS +12.2*** +15.7***
Adjusted for age and sex Mean 28.9 (27.0-30.9) 27.9 (24.8-30.9) 34.2 (30.1-38.4) 39.5 (37.2-41.9)
Diff 1 -10.6*** -11.6*** -5.3* Base
Diff 2 Base -1.1
NS +5.3* +10.6***
Adjusted for block
g
(fixed-effects model) Mean 29.2 (28.1-30.4) 27.6 (25.9-29.4) 31.6 (29.1-34.1) 40.1 (38.6-41.5)
Diff 1 -10.8*** -12.4*** -8.5*** Base
Diff 2 Base -1.6
NS +2.4
NS +10.8***
(random-effects model) Mean 29.6 (25.6-33.5) 28.0 (23.9-32.1) 32.2 (27.8-36.7) 40.8 (36.9-44.8)
Diff 1 -11.3*** -12.8*** -8.6*** Base
Diff 2 Base -1.5
NS +2.7
NS +11.3***
aBased on data in Table 3. The table shows the mean forced expiratory volume in 1 second (FEV1) decline in millilitres per year in the four smoking groups with
95% confidence interval (95% CI) and also the mean differences from continuing smokers (Diff 1) and from never smokers (Diff 2), with statistical significance
indicated. ***P < 0.001, **P < 0.01, *P < 0.05 and NS P ≥ 0.05.
bNever smoked by end of follow-up.
cGave up smoking before baseline and did not resume
smoking.
dSmoked at baseline, but not at end of follow-up.
eSmoked at baseline and at end of follow-up.
fUsing all estimates in Table 3 except the 8 estimates
for ages 25-74 for study 29.
gA block is a row in Table 3 consisting of a set of results for the same study and stratifying variables.
hUsing all estimates in Table 3,
except the 40 estimates in study 29 and the 2 estimates in study 45 without SEs.
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Page 15 of 29Differences in betas between continuing smokers and
those who gave up smoking
The data in Table 3 allow the calculation of 63 within-
block differences in beta between continuing smokers
and quitters and 60 within-block differences between
continuing smokers and ex-smokers. Of the 123 differ-
ences, 21 have no SE (20 in study 29 and 1 in study 45),
so these data could not be used in weighted analyses.
The mean difference between continuing smokers and
quitters is estimated as 11.2 mL/yr (95% CI, 7.0 to 15.3),
based on unweighted analysis of 61 betas, and 7.1 mL/yr
(95% CI, 4.7 to 9.6) based on weighted analysis of 53
betas, while the difference between continuing smokers
and ex-smokers is estimated as 14.9 mL/yr (95% CI,
11.5 to 18.3) based on unweighted analysis of 58 betas
and as 12.3 mL/yr (95% CI, 8.7 to 16.0) based on
weighted analyses of 49 betas.
Variation by age, sex and study characteristics in
differences in beta between continuing smokers and
those who gave up smoking
There is little consistent evidence that differences in beta
between continuing smokers and those who gave up
smoking vary meaningfully by age (adjusted for sex) or sex
(adjusted for age). There is significant variation by sex (P <
0.001) in the differences in betas between continuing smo-
kers and ex-smokers in both the unweighted and inverse
variance-weighted analyses, but these differences are due
to larger differences where estimates are for the sexes
combined, with five of the seven estimates deriving from
one study (43). No significant variation is seen by sex in
the difference in beta between continuing smokers and
quitters. Variation by age (P < 0.001) in the difference in
beta between continuing smokers and ex-smokers is seen
in the weighted analyses, but this does not follow any
trend, with the differences being larger for ages 40-49
(18.7 mL/yr, based on n = 12 betas) and ages 50-69
(14.5 mL/yr, n = 23) than for ages <40 (6.3 mL/yr, n =6 )
and ages 70+ (9.9 mL/yr, n = 8), and is not evident in the
unweighted analyses. Variation by age is also evident for
the difference between continuing smokers and quitters,
but this is evident only in the unweighted analyses (P <
0.001), with differences being larger for ages <40 (28.2
mL/yr, n = 10) than for ages 40-49 (7.8 mL/yr, n = 17),
ages 50-69 (10.2 mL/yr, n = 25) or ages 70+ (1.1 mL/yr,
n =9 ) .
After adjustment for age and sex, there is little evi-
dence of variation in either difference by length of fol-
low-up period, continental location of study, final
follow-up year, year of publication or study type. There
is, however, a consistent tendency for the difference to
be greater where the estimates relate to patients with
specific respiratory diseases than where they relate to
the general population. For the difference between
continuing smokers and quitters, the excess difference
associated with having respiratory disease is 21.6 mL/yr
(P < 0.05) in unweighted analyses (using 61 betas, with
3 relating to subjects with respiratory disease) and 31.3
mL/yr (P < 0.05) in inverse variance-weighted analyses
(using 53 betas, 3 for subjects with respiratory disease).
For the difference between continuing smokers and ex-
smokers, the excess is 12.3 mL/yr (P <0 . 0 5 )i n
unweighted analyses (using 58 betas, 8 for subjects with
respiratory disease) and 4.8 mL/yr (not significant) in
weighted analyses (using 49 betas, 8 for subjects with
respiratory disease).
Relationship of beta to amount smoked in continuing
smokers
As noted above, 166 of the estimates of beta relate to
dose-response relationships. Table 6 presents the data
for those 74 estimates which concern continuing smo-
kers, where the unit of exposure is cigarettes per day
and where the subjects stayed in the same exposure
group between the start and end of follow-up. Eighteen
estimates were excluded because they concerned quit-
ters, and 44 were excluded because the unit of expo-
sure was not cigarettes per day or the level of
exposure was undefined at follow-up. Of the remaining
104 estimates, 30 were excluded and of those, 12 were
excluded because the level of exposure differed
between start and follow-up and 18 were excluded (in
studies 13 and 31) as preference was given to estimates
adjusted for the most variables. Of the 74 betas shown,
36 are from study 29, with 30 individual age betas
without CI and 6 combined age estimates with CI. CIs
are available for all the other 38 estimates derived
from 6 studies. There are 26 “blocks” of independent
dose-response relationships.
Some dose relationships are evident from inspection,
with the betas being higher for the highest consumption
than for the lowest consumption in every block, except
for one block where the betas are the same. After
adjustment for block, the estimated increase in beta per
cigarette per day is 0.33 (95% CI, 0.22 to 0.44) in
unweighted analysis based on 68 betas and 0.33 (95%
CI, 0.20 to 0.45) in inverse variance-weighted analysis
based on 44 betas.
Relationship of some other factors to beta and
differences in betas between smoking groups
A number of the studies present betas separately by
level of factors other than age, sex or study characteris-
tics. Table 7 summarizes trends in beta by level for
those factors for which data were available for continu-
ing smokers and also for quitters and/or ex-smokers.
With the notable exception of study 4, which reports a
strong tendency for beta to decline with reducing FEV1,
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Page 16 of 29both in continuing smokers and quitters, the results
from studies 5, 13 and 45 are consistent in demonstrat-
ing a strong tendency for betas in all three smoking
groups to be greater where there is evidence of reduced
lung function as determined by low FEV1, forced vital
capacity (FVC) or presence of mild obstruction. The
trend in betas is generally greater in continuing smokers
than in quitters or ex-smokers, though the difference in
trends between continuing smokers and either quitters
or ex-smokers is significant in only one case: study 5, in
which a marked trend is seen in continuing smokers,
but no trend is seen in ex-smokers.
There is also evidence from study 43 that, in continu-
ing smokers, beta increases with increasing number of
doctor visits for lower respiratory infection. Though no
such increase is seen in ex-smokers, the difference in
trends is not statistically significant.
No clear evidence of an association with betas within
or between smoking groups is evident in respect of
respiratory symptoms at baseline (study 29), bronchodi-
lator responsiveness (studies 34 and 35) or histamine
responsiveness (study 32). The results from study 7 also
do not suggest any marked relationship of beta to occu-
pational exposure, though lack of SEs limits detailed
interpretation.
Discussion
A major objective of our review is to quantify and com-
p a r et h er a t eo fF E V 1 decline (beta) in those who con-
tinue to smoke (continuing smokers) and those who
Table 5 Relationship of beta (in mL/yr) to study characteristics adjusted for smoking group, sex and age
Unweighted analysis Inverse variance-weighted analysis
Factor Level Number of betas Beta (95% CI) P value
a Number of betas Beta (95% CI) P value
a
Sex
b Males 168 35.8 (33.1-38.4) Base 150 34.6 (32.7-36.5) Base
Females 88 23.9 (20.2-27.7) — 72 28.3 (26.3-30.3) —
Both 39 38.2 (32.5-43.9) NS 39 40.7 (36.2-45.3) +
Age
c < 40 47 13.2 (8.2-18.3) Base 39 28.7 (25.8-31.5) Base
40-49 78 33.9 (30.0-37.8) +++ 68 42.8 (39.6-46.1) +++
50-69 123 37.8 (34.7-41.0) +++ 115 32.1 (30.1-34.1) NS
70+ 47 35.8 (30.7-40.9) +++ 39 27.9 (25.2-30.6) NS
Length of follow-up period Per year 295 -0.16 (-0.57 to 0.25) NS 261 -0.03 (-0.27 to 0.21) NS
Continent North America 148 30.3 (27.5-33.1) Base 114 29.0 (26.1-32.0) Base
Europe 85 36.7 (32.9-40.5) ++ 85 34.8 (31.5-38.1) ++
Asia 28 26.3 (19.7-32.8) NS 28 31.6 (28.2-35.1) NS
Australasia 12 41.9 (31.6-52.1) + 12 42.1 (27.5-56.7) NS
Multicountry 22 34.9 (27.2-42.7) NS 22 34.3 (30.0-38.6) NS
Final follow-up year < 1980 78 27.0 (23.3-30.6) Base 78 25.7 (22.8-28.6) Base
1980-1989 98 42.3 (39.1-45.4) +++ 64 37.9 (34.8-41.1) +++
1990-1999 91 26.0 (22.7-29.3) NS 91 27.6 (25.0-30.3) NS
2000+ 28 35.6 (29.3-42.0) + 28 35.8 (33.1-38.4) +++
Publication year < 1980 26 27.1 (20.1-34.1) Base 26 26.3 (20.5-32.0) Base
1980-1989 129 33.2 (30.2-36.3) NS 129 35.0 (32.1-37.9) ++
1990-1999 99 34.2 (30.7-37.6) NS 65 35.1 (32.5-37.8) ++
2000+ 41 30.0 (24.4-35.5) NS 41 30.2 (27.9-32.4) NS
Population type General 266 32.5 (30.4-34.6) Base 232 32.7 (31.4-34.1) Base
Diseased 29 32.9 (25.8-40.1) NS 29 28.3 (22.3-34.4) NS
Study type Prospective 275 32.9 (30.8-35.0) Base 243 32.7 (31.4-34.1) Base
intervention 20 27.6 (19.2-36.0) NS 18 28.4 (22.6-34.3) NS
a+++, —P < 0.001; ++, – P < 0.01; +, - P < 0.05; NS P ≥ 0.05 with positive signs indicating significantly higher betas than the base level and negative signs
indicating significantly lower betas.
bAdjusted for smoking group and age only.
cAdjusted for smoking group and sex only.
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Page 17 of 29give up smoking (quitters and ex-smokers). In an ideal
world, this review would involve a number of large stu-
dies in which smoking habits, FEV1 levels and relevant
confounding variables were measured at regular inter-
vals and in which betas could be assessed separately for
continuing smokers and for those who gave up, by time
quit, on the basis of recently recorded smoking data.
One could then distinguish between alternative possible
models for FEV1 decline. For example, it might be that,
following giving up smoking (and not subsequently
restarting), the rate of decline in FEV1 drops immedi-
ately to a lower level than that of continuing smokers
and continues at this level. Alternatively, it might be
that, on giving up smoking, the rate of decline drops
only slightly at first but then increases over time until it
reaches a fixed level. The theory suggested by Fletcher
and Peto [6] implies that the first situation may obtain,
but there are few studies which present data in enough
detail to distinguish such alternatives.
Anthonisen et al. [7], on the basis of a randomized
clinical trial of smoking intervention (The Lung Health
Study, study 43), did present a figure that suggests that
giving up smoking leads to a reduced (and constant)
beta quite quickly, though their study also suggests that
in the first year or so after giving up, FEV1 levels may
actually increase slightly. However, such data seem
extremely rare, and the studies considered here include
many in which FEV1 w a sr e c o r d e da to n l yt w ot i m e
Table 6 Data on FEV1 decline (in mL/year) in continuing smokers by amount smoked
a
Stratifying variables
Study no. Reference Sex Age Other
b Amount smoked
(cigarettes/day)
c
Beta (SE)
4 Burchfiel et al. [11] M 45-68 - 1-19, 20-29, 30-39, 40+ 29.8 (3.5), 32.4 (2.0), 35.5 (2.8), 34.3 (2.7)
12 Ferris et al. [29] M 25-74 - 1-24, 25+ 0.0 (5.7), 6.7 (5.8)
F 25-74 - 1-24, 25+ 1.7 (4.4), 1.7 (8.3)
13 Fletcher et al. [6] M 30-59 F1 1-5, 6-15, 16-25, 26+ 45.0 (5.0), 55.0 (4.0), 74.0 (5.0), 63.0 (6.0)
M 30-59 F2 1-5, 6-15, 16-25, 26+ 37.0 (6.0), 49.0 (4.0), 51.0 (4.0), 45.0 (10.0)
M 30-59 F3 1-5, 6-15, 16-25, 26+ 39.0 (4.0), 39.0 (4.0), 38.0 (5.0), 52.0 (11.0)
22 Lange et al. [42] M 20-54 - 1-14, 15+ 22.0 (6.0), 42.0 (5.0)
M 55+ - 1-14, 15+ 52.0 (3.0), 56.0 (6.0)
F 20-54 - 1-14, 15+ 17.0 (4.0), 30.0 (4.0)
F 55+ 1-14, 15+ 39.0 (3.0), 48.0 (5.0)
29 Xu et al. [54] M 25-34 - 1-14, 15-24, 25+ 36.5, 20.6, 41.7
M 35-44 - 1-14, 15-24, 25+ 30.4, 40.3, 39.0
M 45-54 - 1-14, 15-24, 25+ 55.0, 57.4, 68.8
M 55-64 - 1-14, 15-24, 25+ 49.0, 53.8, 68.5
M 65-78 - 1-14, 15-24, 25+ 66.8, 54.1, 73.4
M 25-74 - 1-14, 15-24, 25+ 37.4 (6.0), 47.2 (3.6), 59.9 (3.5)
F 25-34 - 1-14, 15-24, 25+ 16.5, 21.9, 28.0
F 35-44 - 1-14, 15-24, 25+ 28.9, 35.8, 36.9
F 45-54 - 1-14, 15-24, 25+ 32.5, 45.7, 37.8
F 55-64 - 1-14, 15-24, 25+ 42.7, 52.0, 50.4
F 65-78 - 1-14, 15-24, 25+ 29.4, 47.9, 37.4
F 25-74 - 1-14, 15-24, 25+ 31.2 (2.4), 42.0 (1.8), 38.9 (2.5)
31 Tashkin et al. [57] M 25-59 - 1-20, 21+ 77.8 (6.2), 81.8 (5.0)
F 25-59 - 1-20, 21+ 52.3 (3.3), 61.7 (3.7)
32 Xu et al. [4] M 25-54 - 1-14, 15-24, 25+ 18.8 (5.3), 26.3 (4.2), 33.2 (4.9)
F 25-54 - 1-14, 15-24, 25+ 15.0 (4.0), 20.4 (5.1), 30.1 (7.6)
aFor details of length of follow-up and number of adjustment variables, see Table 3.
bOther stratifying variables are indicated as follows: F1, F2, F3 = forced
expiratory volume in 1 second (FEV1) at baseline <55, 55-64, 65+ cL/m
3.
cFor the purposes of estimating mean cigarettes/day for an interval, a simple average of
the upper and lower limits was used, with the upper limit for the final interval taken as 50 cigarettes/day.
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Page 18 of 29Table 7 Trends in betas (mL/yr) by level of various factors
a
Trend (SE)
b
Factor Levels Study
no.
Ref. Sex Age range at
baseline
Continuing
smokers
Quitters Ex-
smokers
Baseline FEV1 (cL/m
3) 65+, 55-64, 1-54 13 Fletcher et al.
[6]
Male 30-59 Mean 10.0 (1.5)*** 4.0 (8.8) 4.8 (3.5)
Diff
c Base 6.2 (8.9) 5.1 (3.8)
Baseline FEV1 (mL) High, middle, low 4 Burchfiel et al.
[11]
Male 45-68 Mean -24.8 (1.6)*** -16.1
(5.3)**
Diff Base -8.8 (5.6)
Baseline FEV1 (mL/m
3) 500+, 1-499 45 Townsend [73] Male 35-57 Mean 28.1 (8.6)** 21.2
(15.6)
Diff Base 6.9
(17.8)
Baseline FEV1/FVC (%) 80+, 70-79, 1-69 5 Burrows et al.
[10]
Male 20-70 Mean 27.9 (4.2)*** -3.4 (5.5)
Diff Base 31.3 (6.9)
***
Obstruction at
baseline
None, mild 13 Fletcher and
Peto [31]
Male 30-59 Mean 24.8 (16.4) 7.0 (9.4)
Diff Base 17.8
(18.9)
Obstruction at
baseline
None, mild 13 Fletcher et al.
[6]
Male 30-59 Mean 22.1 (11.4) 4.0 (8.5)
Diff Base 18.1
(14.3)
Doctor visits for LRI
d 0-0.24, 0.25-0.49, 0.50-0.99,
1.00-1.49, 1.50+
43 Kanner et al.
[70]
Male 35-60 Mean 3.5 (0.8)*** 2.9 (1.9)
Diff Base 0.7 (2.0)
Respiratory symptoms
at baseline
No, Yes 29 Sherman et al.
[53]
Male 25-74 Mean 4.6 (4.0) 4.3 (3.1)
Diff Base 0.3 (5.1)
Respiratory symptoms
at baseline
No, Yes 29 Sherman et al.
[53]
Female 25-74 Mean 1.9 (2.4) -5.9 (5.0)
Diff Base 7.8 (5.5)
Bronchodilator
responsiveness
No, Yes 34 Vollmer et al.
[60]
Both 25-54 Mean 22.0 (30.1) 46.0
(22.7)
Diff Base -24.0
(37.7)
Bronchodilator
responsiveness
No, Yes 35 Vollmer et al.
[60]
Both 25-54 Mean 10.0 (13.7) 14.0
(20.0)
Diff Base -4.0
(24.2)
Histamine
responsiveness
No, Yes 32 Rijcken et al.
[5]
Male 25-54 Mean 3.2 (7.9) 4.5 (9.4)
Diff Base -1.3
(12.3)
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Page 19 of 29points, and some where, despite FEV1 being recorded at
multiple time points, the data presented relate only to
the average beta over the whole follow-up period. Stu-
dies where results are presented for more than one time
period are relatively rare, and some of these studies do
not adequately characterize smoking status at the begin-
ning and end of each period studied. To allow assess-
ment of FEV1 decline from a reasonable number of
studies, therefore, we have summarized the data relating
to the experience of a smoking group over a defined
period, with the key information recorded being the
smoking habits of that group at the beginning and end
o ft h ep e r i o da n dt h eb e t ae stimated over the period
studied. While the limitations of the available data mean
that we cannot estimate the exact shape of the decline
in FEV1 over time, our approach (which implicitly
assumes a linear decline) is supported by the lack of
relationship noted between beta and length of follow-up
period (see Table 5).
Before discussing the results obtained, some other lim-
itations of the data should be noted. Many of the 47
studies with relevant data are old, with 16 starting
before 1970 and 42 beginning before 1990, and almost
half of the studies provided data only for men. A num-
ber of the studies are quite small, with nine involving
less than 100 individuals, implying very limited numbers
in some of the smoking groups. In many of the studies,
there was no adjustment for any variables, not even age
Table 7 Trends in betas (mL/yr) by level of various factors
a (Continued)
Histamine
responsiveness
No, Yes 32 Rijcken et al.
[5]
Female 25-54 Mean 5.8 (8.2) 5.9 (12.0)
Diff Base -0.1
(14.5)
Occupational
exposure
None, low, high 7 Sunyer et al.
[24]
Male 20-44 Mean 0.8 -1.1
Diff Base 1.8
Occupational
exposure
None, low, high 7 Sunyer et al.
[24]
Female 20-44 Mean 1.2 6.2
Diff Base -5.0
Exposure to gas and
fumes
None, low, high 7 Sunyer et al.
[24]
Male 20-44 Mean 1.5 -2.9
Diff Base 4.4
Exposure to gas and
fumes
None, low, high 7 Sunyer et al.
[24]
Females 20-44 Mean -3.2 5.6
Diff Base -8.9
Biological dust
exposure
None, low, high 7 Sunyer et al.
[24]
Males 20-44 Mean 0.2 2.5
Diff Base -2.3
Biological dust
exposure
None, low, high 7 Sunyer et al.
[24]
Females 20-44 Mean 6.8 5.6
Diff Base 1.2
Mineral dust exposure None, low, high 7 Sunyer et al.
[24]
Males 20-44 Mean 0.0 2.3
Diff Base -2.3
Mineral dust exposure None, low, high 7 Sunyer et al.
[24]
Females 20-44 Mean 2.0 6.5
Diff Base -4.5
aFEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
bThe trend is the estimated weighted increase in beta per level of exposure, except for
study 7 where it is unweighted as no SEs are available. Trends are underlined if significant at P < 0.05.
cThe difference in the trend compared to continuing
smokers. Significant differences in trends are indicated by *P < 0.05, **P < 0.01 and ***P < 0.001.
dLRI, lower respiratory infection.
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Page 20 of 29or height. Smoking habits were not always defined at
both the beginning and end of the time interval studied.
FEV1 results were virtually never recorded after bronch-
odilator therapy as recommended for the diagnosis of
COPD [8,9]. For many of the studies, estimates of the
variability of the betas are not available, though for
some estimates, the variability could be derived on the
basis of SD estimates for other studies and knowledge
of sample size. There are very limited data on how betas
for a given smoking group vary by other factors of inter-
est, as is evident from Table 7. It should also be pointed
out that although there is a reasonable amount of infor-
mation on how beta varies by amount smoked per day
in continuing smokers (see Table 6), there are no such
data for those who give up smoking. Also, comparisons
of continuing smokers with quitters or ex-smokers are
very often unadjusted for the amount smoked per day at
the time when the quitters or ex-smokers were still
smoking. We have not attempted to assess the indivi-
dual studies for quality and susceptibility to bias, partly
because there are no generally recognized methods for
doing so for observational epidemiological studies, partly
because a one-dimensional score for a study cannot
really adequately summarize the multiple facets of its
quality, and partly as differentially weighting (or reject-
ing) results from different studies based on an inevitably
subjective score is always contentious, perhaps especially
so when the study was supported by the tobacco
industry.
Another possible limitation of our work concerns the
completeness of our database, given the difficulty of
being certain that all the relevant literature has been
obtained, particularly when studies have been conducted
over such a long period and given that some studies
which clearly have the ability to provide relevant results
seem never to have published findings in an appropriate
format.
Despite all these limitations, we believe that the data-
base assembled is of value in assessing the relationship
of smoking habits, and particularly giving up smoking,
to the magnitude of beta. A number of main conclu-
sions can be drawn from our analyses.
First, beta in never smokers is clearly less than that in
continuing smokers. The results summarized in Table 4
suggest that, whereas beta in continuing smokers is over
40 mL/yr, it is less than 30 mL/yr in never smokers.
The difference exceeds 10 mL/yr and is highly signifi-
cant (P < 0.001) in all the analyses shown. Though there
is variation between blocks (that is, rows of Table 3) in
the level of betas, the higher betas in continuing smo-
kers is evident in virtually every block.
It is also clear that betas in ex-smokers, who gave up
before the start of the period over which the FEV1 was
measured, are quite similar to those in never smokers.
In the inverse variance-weighted analyses adjusted for
block, beta was estimated as 27.6 mL/yr, a nonsignifi-
cant 1.6 mL/yr lower than the estimate of 29.2 mL/yr
for never smokers. Estimates for quitters (31.6 mL/yr
for the same analyses) tend to be somewhat higher than
for never smokers or ex-smokers, but are clearly lower
than those in continuing smokers. Though variability in
the estimates does not make the intermediate position
of quitters well-defined, the results can plausibly be
explained by the quitters having smoked for part of the
period during which the betas were estimated. Data
were not available to relate time of quitting to beta.
Our analyses also show that, in continuing smokers,
there is a clear dose relationship with amount smoked,
with an increase in beta of 0.33 mL/yr per cigarette/day.
Though the data are relatively limited, they are consis-
tent in showing a beta greater in the heaviest smokers
than in the lightest smokers.
Four of the studies (4, 5, 13 and 45) provide informa-
tion relating beta to smoking group by level of lung
function, as determined by FEV1, FEV1/FVC or presence
of mild obstruction. Studies 5, 13 and 45 present results
which seem consistent with what has been termed the
“horse-racing effect” [6,10], whereby reduced lung func-
tion predicts a rapid rate of decline simply because the
rapid decline produced the reduced level of lung func-
tion in the first place. However, study 4 presents results
which seem totally inconsistent with this finding, parti-
c u l a r l yi nc o m p a r i s o nw i t hs t u d y1 3 .T h er e s u l t ss h o w n
in Table 7 for this study are for the first 2 years follow-
up, as SEs could not be derived for the full 6 years of
follow-up. Though the strong tendency for betas to be
higher in continuous smokers and quitters with a high
baseline FEV1 seen in the first 2 years of follow-up
seems not so marked for the full 6 years follow-up (see
Table 5 of the source paper [11]), there is still no evi-
dence of the horse-racing effect, as the authors note.
Why this inconsistency is seen is not clear.
In all four studies, the trend in beta in relation to
reduced lung function is weaker in quitters and ex-smo-
kers than in continuing smokers. However, only in
study 5, where a tendency for low baseline FEV1/FVC to
predict an increased beta is clearly evident in continuing
smokers but not evident in ex-smokers, is the difference
from continuing smokers significant at P < 0.05.
The other factors considered in Table 7 (doctor visits
for lower respiratory infection, bronchodilator respon-
siveness, histamine responsiveness and various aspects
of occupational exposure) generally show no relation-
ship with beta in continuing smokers, quitters or
ex-smokers or with the difference in beta between conti-
nuing smokers and the other two smoking groups. The
only exception was the significant tendency for beta in
continuing smokers to increase with doctor visits. The
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coming from a single study. While there do not appear
to be other studies that allow assessment of differences
in trends between continuing smokers and quitters or
ex-smokers, it is possible that additional studies may
provide evidence for the association in smokers or in
the whole population, regardless of smoking habits.
Because this review is mainly concerned with the study
of effects of giving up smoking, we did not consider stu-
dies which did not report results for quitters or ex-
smokers.
The same applies to the study characteristics considered
in Table 5. Had we been specifically trying to answer the
question whether beta varies by age or sex, much addi-
tional literature would have been considered. Of more
interest is whether these study characteristics are related
to the difference in betas between continuing smokers and
quitters or ex-smokers. The main finding here is that the
difference in betas between continuing smokers and quit-
ters is greater where the estimates relate to individuals
with specific respiratory diseases than when they relate to
the general population. This is consistent with the theory
that a susceptible proportion of smokers suffer a more
rapid decline in lung function than do other smokers or
those who have given up smoking. This susceptible pro-
portion would be more likely both to have reduced lung
function and be diagnosed with respiratory disease [6].
Other than having a greater beta, having reduced lung
function, and being more likely to be diagnosed as having
COPD, our review does not cast any light on characteris-
tics linked to susceptibility in smokers.
For the purposes of designing a study comparing smo-
kers and users of new-generation nicotine delivery pro-
ducts, it would be useful to know the level of decline in
FEV1 one would expect over a defined time period in
continuing smokers and those who give up smoking.
Our analyses, presenting the results in terms of average
FEV1 decline per year (beta) assume that the rate of
decline is approximately constant over time, an assump-
tion which is supported by the analyses presented in
Table 5. Though this analysis is uncertain, being ecolo-
gical in nature (as the relationship of beta to length of
follow-up is evaluated only between studies), the
strength of the association is clearly not strong. This
suggests that our estimates of beta, based on 39 studies
with an average follow-up period of 9 years, can be
taken to apply both to short-term studies of say 5 years
and to longer-term studies of, say, 15 years. It would
seem reasonable to design a study comparing FEV1
declines in continuing smokers of conventional cigar-
ettes and switchers to new products, assuming that beta
reduces a somewhat conservative 10 mL/yr on quitting
and that it reduces by perhaps 8 or 9 mL/yr in the
switchers, provided that there is good toxicological
evidence that these new products have little or no
respiratory effect. For a 5-year study, we estimate that a
comparison of continuing smokers and switchers would
require about 120 smokers per group to have 80%
power to detect a difference of 8 mL/yr at the P <0 . 0 5
significance level, assuming participants do not change
their smoking habits and ignoring dropouts. To detect a
d i f f e r e n c eo f9m L / y rw o u l dr e q u i r ea b o u t9 5s m o k e r s
per group.
Conclusions
While the available data have a number of limitations, it
is possible to draw a number of conclusions relating to
the annual rate of FEV1 loss (beta) in continuing smo-
kers, quitters, ex-smokers and never smokers. Continu-
ing smokers have a beta that is clearly greater, by more
than 10 mL/yr, than in never smokers and is positively
related to the number of cigarettes smoked per day.
Betas in ex-smokers are similar to those in never smo-
kers, and betas in quitters are only slightly greater.
There is no clear evidence that differences in betas
between continuing smokers and those who have given
up smoking depend on age or sex, but differences are
greater in studies of populations with respiratory disease
than in general population studies. Some, but not all,
studies suggest that betas are greater in those with
reduced lung function, particularly in continuing
smokers.
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